DENTSPLY SIRONA Inc. (NASDAQ:XRAY) does about 2.29M shares in volume on a normal day but saw 1644772 shares change hands in Monday trading. The company now has a market cap of 7.96B USD. Its current market price is $37.41, marking an increase of 1.19% compared to the previous close of $36.97. The 52 week high reached by this stock is $58.70 whilst the lowest price level in 52 weeks is $26.48. The script in recent trading has seen the stock touch a high of $37.81 and a low of $37.05.
DENTSPLY SIRONA Inc. (XRAY) has a 20-day trading average at $34.11 and the current price is -36.27% off the 52-week high compared with 41.28% distance from its 52-week low. The 50-day simple moving average of the closing price is $32.09 and its 200-day simple moving average is $34.70. If we look at the stock’s price movements over the week, volatility stands at 2.16%, which increases to 3.06% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 73.56 to suggest the stock is overbought.
The consensus objective for the share price is $34.91, suggesting that the stock has a potential downside of -7.16% over the period.
FactSet Research has provided data showing that 13 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 5 analysts have rated it as a buy and 8 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
UBS upgraded its price target at $58-$47.
The current price level is 10.66%, 17.25%, and 7.65% away from its SMA20, SMA50, and SMA200 respectively, with the XRAY price moving above the 50-day SMA on January 23. DENTSPLY SIRONA Inc. (XRAY) stock is up 2.35% over the week and 21.15% over the past month. Its price is 17.49% year-to-date and -29.83% over the past year.
The stock last released its quarterly earnings report for quarter ended 3/30/2022, with the company’s earnings per share (EPS) of $0.52 below consensus estimates by -$0.04. The company’s next earnings report is expected on 05/09/2023, with forecasts estimating quarterly EPS at $0.54 and $2.38 for whole year. XRAY’s earnings per share are forecast to shrink by -17.10% this year and 9.70% over next year. Expected sales for next quarter are $1.04 billion, which analysts say will come at $4.1 billion for the current fiscal year and next year at $4.22 billion. In addition, estimates put the company’s current quarterly revenue at an average of $1.01 billion.
Its 12-month price target is $34.00. To reach the target analysts have set, the stock logically needs to shrink -7.16 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $29.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $40.00.
Outstanding shares total 214.90M with insiders holding 0.41% of the shares and institutional holders owning 101.59% of the company’s common stock. The company has a return on investment of 6.70% and return on equity of -18.40%. The forward price to earnings ratio is 20.33. The beta has a value of 0.93. Price to book ratio is 2.23 and price to sales ratio is 1.99.
First Eagle Global Fund isn’t the only investment manager who changed stakes and is followed by Nuance Mid Cap Value Fund, which added 1.5 million shares to end up with 6,654,825 shares worth $211.89 million. Vanguard Total Stock Market Index raise their holdings by 1.09% in the company over the course of the most recent quarter. It now holds a 3.05% position in DENTSPLY SIRONA Inc. thanks to 6.55 million shares amounting to $208.56 million.